Erasca Inc Market Cap ($4.91 Billion)
Market Cap & Net Worth: Erasca Inc (ERAS)
Erasca Inc market cap. Erasca Inc (NASDAQ:ERAS) has a market capitalization of $4.91 Billion ($4.91 Billion) as of November 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #3517 globally and #1260 in its home market, demonstrating a -2.36% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Erasca Inc's stock price $14.05 by its total outstanding shares 349762035 (349.76 Million). Also see cash efficiency ratio of Erasca Inc for how efficiently the company converts equity into cash flow.
Erasca Inc Market Cap History (2021–2026)
Erasca Inc market cap history from 2021 to 2026. Data shows change from $5.45 Billion to $4.91 Billion (-3.98% CAGR). Check Erasca Inc stock quote for real-time trading data and today's change.
Index Memberships
Erasca Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.60 Trillion | 0.19% | #91 of 976 |
|
NASDAQ Composite
IXIC
|
$39.84 Trillion | 0.01% | #404 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.83 Trillion | 0.27% | #59 of 263 |
Weight: Erasca Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Erasca Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Erasca Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Erasca Inc growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ERAS by Market Capitalization
Companies near Erasca Inc in the global market cap rankings as of November 3, 2026. Also see Erasca Inc (ERAS) total assets for a full breakdown of the balance sheet.
Key companies related to Erasca Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Erasca Inc (2021–2026)
Market capitalization of Erasca Inc from 2021 to today. Between 2021 and today, Erasca Inc's market cap moved from $5.45 Billion to $ 4.91 Billion, with a yearly change of -3.98%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $4.91 Billion | +277.69% |
| 2025 | $1.30 Billion | +48.21% |
| 2024 | $877.90 Million | +17.84% |
| 2023 | $744.99 Million | -50.58% |
| 2022 | $1.51 Billion | -72.34% |
| 2021 | $5.45 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Erasca Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.91 Billion USD |
| MoneyControl | $4.91 Billion USD |
| MarketWatch | $4.91 Billion USD |
| marketcap.company | $4.91 Billion USD |
| Reuters | $4.91 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Erasca Inc
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid … Read more